2. Lankhorst CE, Wish JB. Anemia in renal disease: Diagnosis and management. Blood Reviews 24 (2010) 39-47. Disponible de forma online en: http://www.bloodreviews.com/article/S0268-960X(09)00054-X/fu.... Último acceso en noviembre de 2013
3. Singh et al. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. New England Journal of Medicine 2006; 355:2085-98
4. McMurray JJV, Parfrey PS et al. KDIGO (Kidney Disease - Improving Global Outcomes) Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney International Supplements VOL 2 | ISSUE 4 | AUGUST (2) 2012, 279; doi:10.1038/kisup.2012.37. Disponible de forma online en: http://www.nature.com/kisup/journal/v2/n4/index.html. Último acceso en noviembre de 2013
5. Besarab A et al. Evaluation of hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for haemoglobin correction and maintenance in nondialysis chronic kidney disease patients for 16 and 24 weeks. Abstract FP215. Nephrology Dialysis Transplantation Volume 27: Suplemento 2; página ii144 mayo de 2012. Disponible de forma online en: http://ndt.oxfordjournals.org/content/27/suppl_2/ii133.full.... . Último acceso en noviembre de 2013
6. Bouche. First-in-class anaemia drugtakes aim at Amgen's dominion. Nature biotechnology 2013; 31:11
7. Zoccali C et al. Epidemiology of CKD in Europe: an uncertain scenario. Nephrology Dialysis Transplantation (2010) 25: 1731-1733. Disponible de forma online en: http://ndt.oxfordjournals.org/content/25/6/1731.full. Último acceso en noviembre de 2013
8. The Alarming Rise in Chronic Kidney Disease in Europe. How to deal with this costly problem. European Kidney Health Alliance. Disponible de forma online en: http://www.era-edta.org/images/2013_EKHA_Call_to_Action_ANNE... [http://www.era-edta.org/images/2013_EKHA_Call_to_Action_ANNE... .pdf ]. Último acceso en noviembre de 2013
9. Lameire N et al. Chronic kidney disease: A European perspective. Kidney International, Vol. 68, Supplement 99 (2005), pp. S30-S38. Disponible de forma online en: http://www.nature.com/ki/journal/v68/n99s/full/4495665a.html. Último acceso en noviembre de 2013
CONTACTO: Mindy Dooa, director de comunicaciones empresariales de AstellasPharma Europe Ltd., móvil: +44(0)7826-912339, e-mail:Mindy.Dooa@astellas.com
